Geode Capital Management, LLC Finch Therapeutics Group, Inc. Transaction History

Geode Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.34 - $0.56 $472 - $778	-1,390 Reduced 0.66%	208,320 $81,000
Q4 2022 Feb 13, 2023	SELL	$0.36 - $56.4 $169 - $26,508	-470 Reduced 0.22%	209,710 $100,000
Q3 2022 Nov 14, 2022	BUY	$1.75 - $51.3 $186,784 - $5.48 Million	106,734 Added 103.18%	210,180 $351,000
Q2 2022 Aug 12, 2022	SELL	$1.91 - $5.11 $108,829 - $291,162	-56,979 Reduced 35.52%	103,446 $293,000
Q1 2022 May 13, 2022	BUY	$5.02 - $10.47 $46,500 - $96,983	9,263 Added 6.13%	160,425 $806,000
Q4 2021 Feb 11, 2022	SELL	$8.95 - $16.88 $21,363 - $40,292	-2,387 Reduced 1.55%	151,162 $1.51 Million
Q3 2021 Nov 12, 2021	BUY	$12.2 - $16.75 $158,941 - $218,219	13,028 Added 9.27%	153,549 $2 Million
Q2 2021 Aug 13, 2021	BUY	$12.03 - $17.51 $1.69 Million - $2.46 Million	140,521 New	140,521 $1.98 Million

Ticker FNCH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,688,400
Market Cap $546M
Description
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides diffi...

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Geode Capital Management, LLC with notifications on news.